Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Glasgow Renal and Transplant Unit, NHS Greater Glasgow and Clyde, Glasgow, UK.
Heart. 2019 Jun;105(12):938-945. doi: 10.1136/heartjnl-2018-313955. Epub 2018 Dec 4.
Vascular stiffness (VS) and vascular calcification (VC) are surrogate markers of vascular health associated with cardiovascular events. Vitamin K-dependent proteins (VKDP) are associated with VS and VC and require vitamin K for activity. We conducted a systematic review and meta-analysis of: (1) the effect of vitamin K supplementation on VS and VC and (2) association of inactive VKDP levels with incident cardiovascular disease and mortality.
Two authors searched MEDLINE and Embase databases and Cochrane and ISRCTN registries for studies of vitamin K clinical trials that measured effects on VC, VS or VKDP and longitudinal studies assessing effect of VKDP on incident CVD or mortality. Random effects meta-analyses were performed.
Thirteen controlled clinical trials (n=2162) and 14 longitudinal studies (n=10 726) met prespecified inclusion criteria. Vitamin K supplementation was associated with significant reduction in VC (-9.1% (95% CI -17.7 to -0.5); p=0.04) and VKDP (desphospho-uncarboxylated matrix Gla protein; -44.7% (95% CI -65.1 to -24.3), p<0.0001) and uncarboxylated osteocalcin; -12.0% (95% CI -16.7 to -7.2), p<0.0001) compared with control, with a non-significant improvement in VS. In longitudinal studies with median follow-up of 7.8 (IQR 4.9-11.3) years, VKDP levels were associated with a combined endpoint of CVD or mortality (HR 0.45 (95% CI 0.07 to 0.83), p=0.02).
Supplementation with vitamin K significantly reduced VC, but not VS, compared with control. The conclusions drawn are limited by small numbers of studies with substantial heterogeneity. VKDP was associated with combined endpoint of CVD or mortality. Larger clinical trials of effect of vitamin K supplementation to improve VC, VS and long-term cardiovascular health are warranted.
CRD42017060344.
血管僵硬(VS)和血管钙化(VC)是与心血管事件相关的血管健康的替代标志物。维生素 K 依赖性蛋白(VKDP)与 VS 和 VC 相关,并且其活性需要维生素 K。我们进行了一项系统评价和荟萃分析:(1)维生素 K 补充对 VS 和 VC 的影响,(2)无活性 VKDP 水平与心血管疾病事件和死亡率的关系。
两名作者检索了 MEDLINE 和 Embase 数据库以及 Cochrane 和 ISRCTN 注册中心,以查找评估 VC、VS 或 VKDP 影响的维生素 K 临床试验研究,以及评估 VKDP 对心血管疾病事件或死亡率影响的纵向研究。采用随机效应荟萃分析。
符合预定纳入标准的 13 项对照临床试验(n=2162)和 14 项纵向研究(n=10726)。维生素 K 补充与 VC 显著减少相关(-9.1%(95%CI -17.7 至 -0.5);p=0.04)和 VKDP(去磷酸未羧化基质 Gla 蛋白;-44.7%(95%CI -65.1 至 -24.3),p<0.0001)和未羧化骨钙素;-12.0%(95%CI -16.7 至 -7.2),p<0.0001)与对照组相比,VS 无显著改善。在中位随访 7.8(IQR 4.9-11.3)年的纵向研究中,VKDP 水平与 CVD 或死亡率的综合终点相关(HR 0.45(95%CI 0.07 至 0.83),p=0.02)。
与对照组相比,维生素 K 补充可显著降低 VC,但不能降低 VS。由于研究数量较少且存在较大的异质性,得出的结论有限。VKDP 与 CVD 或死亡率的综合终点相关。需要进行更大规模的临床试验,以评估维生素 K 补充对改善 VC、VS 和长期心血管健康的效果。
CRD42017060344。